Johnnie Vigil, MD
General Practice · Albuquerque, NMNPI 1285762377
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,903 of the $4,710 with a category attached, or 82.9%. It is spread thinly across 14 manufacturers, the largest accounting for just 17.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,151 and has fallen 78.6% since, to $460 in 2025. Among general practice clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 133 payments — averaging $35.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$816
- AbbVie$773
- Indivior Inc.$664
- Sunovion Pharmaceuticals Inc.$563
- Gilead$438
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$395
- plus $1K from 8 others
What the payments were for
- Travel & lodging$72515%
- Food & beverage$3,90383%
- Education$832%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 4 | $816 |
| AbbVie(2 entities) | 31 | $773 |
| Indivior Inc. | 30 | $664 |
| Sunovion Pharmaceuticals Inc. | 13 | $563 |
| Gilead | 10 | $438 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 15 | $395 |
| Alkermes, Inc. | 4 | $266 |
| Braeburn Inc. | 5 | $173 |
| AstraZeneca | 2 | $139 |
| Otsuka America Pharmaceutical, Inc. | 2 | $129 |
| Exact Sciences | 6 | $120 |
| Novartis | 5 | $98 |
| Pfizer | 4 | $96 |
| Lilly USA, LLC | 2 | $41 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ClosureFast$725
- ARISTADA$500
- LATUDA$353
- VRAYLAR$243
- ARISTADA INITIO$125
- BREZTRI$123
- SUBLOCADE$122
- REXULTI$104
How this compares
$4,710 in reported general payments places this provider in the 95th percentile of 511 general practice providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 115 | $19,730 |
| VraylarCariprazine Hcl | 11 | $18,168 |
| MounjaroTirzepatide | 15 | $16,037 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 15 | $12,673 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 11 | $12,527 |
| EliquisApixaban | 12 | $6,848 |
| Buprenorphine Hcl | 36 | $1,142 |
| Quetiapine Fumarate | 14 | $930 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 41 | $730 |
| Gabapentin | 58 | $646 |
| Omeprazole | 27 | $618 |
| Novolin 70-30Insulin Nph Hum/Reg Insulin Hm | 11 | $521 |
| Pregabalin | 13 | $493 |
| Clonazepam | 40 | $460 |
| Levothyroxine Sodium | 33 | $383 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $773 | $18,16811 claims |
| Lilly USA, LLCMounjaro | $41 | $16,03715 claims |
| Indivior Inc.Suboxone | $664 | $12,67315 claims |
| PfizerEliquis | $96 | $6,84812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 511 general practice providers in New Mexico.
Other general practice in Albuquerque
- Charles SchlesingerAlbuquerque$347K
- Sandra PaulesAlbuquerque$62K
- Alfred GiomboliniAlbuquerque$20K
- Robert KerschenAlbuquerque$20K
- Drew NewhoffAlbuquerque$17K
- Carissa Greinel-BlumAlbuquerque$13K
- Kendal TrujilloAlbuquerque$12K
- Devon RasmussenAlbuquerque$6K
- Ryan SillAlbuquerque$6K
- Colin FordeAlbuquerque$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.